RPC(SZ:000650) Xin Lang Zheng Quan·2025-10-30 15:12Core Viewpoint - Renhe Pharmaceutical, established in December 1996, is a well-known pharmaceutical company with a strong product line and brand presence in the traditional Chinese medicine and health-related products sector [1] Group 1: Business Overview - The company primarily engages in the production and sale of traditional and Western medicines, raw materials, and health-related products, covering various dosage forms including solid and liquid preparations [1] - As of Q3 2025, Renhe Pharmaceutical reported a revenue of 2.833 billion yuan, ranking 21st out of 69 in the industry, with the industry leader Baiyunshan achieving 61.606 billion yuan [2] - The revenue composition includes 1.388 billion yuan from pharmaceuticals (70.25%), 549 million yuan from health-related products (27.79%), and 38.573 million yuan from other business products (1.95%) [2] Group 2: Financial Performance - The net profit for Q3 2025 was 469 million yuan, ranking 18th in the industry, with the top performer Yunnan Baiyao reporting 4.789 billion yuan [2] - The company's asset-liability ratio stood at 13.08% in Q3 2025, an increase from 10.32% in the previous year, which is significantly lower than the industry average of 32.81% [3] - The gross profit margin for Q3 2025 was 36.43%, down from 37.65% year-on-year, and also below the industry average of 52.44% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 6.42% to 97,700, while the average number of circulating A-shares held per shareholder increased by 6.86% to 13,600 [5] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited ranked fourth with 13.4878 million shares, an increase of 2.0013 million shares from the previous period [5]